Search

Displaying results 7511 - 7520 of 8195 in total
  1. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athe...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  2. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  3. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal ...

  4. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

    Categories: P-glycoprotein inhibitors
  5. Drug

    Vitespen

    go.drugbank.com/drugs/DB06400
    Investigational

  6. Drug

    Technetium Tc-99m tilmanocept

    go.drugbank.com/drugs/DB09266
    Approved

    Due to its relatively small molecular weight and small molecular diameter of 7 nm [A32168], technetium Tc-99m tilmanocept displays more rapid injection site clearance, high sentinel node extraction, and

  7. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    Formebolone, a derivative of androstane, is an anabolic androgenic steroid. It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes.

  8. Drug

    Mycobacterium w. Vaccine

    go.drugbank.com/drugs/DB15798
    Investigational

    As an immunotherapy, M.w is used against leprosy; the compound also shares antigens with M. tuberculosis.

  9. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria.

  10. Drug

    Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine

    go.drugbank.com/drugs/DB15813
    Investigational

    Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins